Study of Plasma Tumor-promoting Factors and Immune Function After Laparotomy, Cytoreductive Surgery and HIPEC vs. PIPAC in Patients With Peritoneal Metastasis

NCT04122885 · clinicaltrials.gov ↗

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Peritoneal Cancer
Chemotherapy-Induced Change

Interventions

COMBINATION_PRODUCT: PIPAC with oxaliplatin
PROCEDURE: Cytoreductive surgery and Hyperthermic IntraPeritoneal Chemotherapy

Sponsor

University Hospital Tuebingen

Collaborators

[object Object]